FDA OIS/OMS merger
This article was originally published in The Gray Sheet
Executive Summary
FDA device center's Office of Information Systems and Office of Management Services are likely to be merged, according to FDA staffers. Donald Sauer joined the device center in January as acting associate director for management and systems, overseeing OIS and OMS ("The Gray Sheet" Feb. 14, In Brief). Sauer took on the duties of the OMS acting director with the departure of Helen Winkle this summer ("The Gray Sheet" July 11, p. 24). A merged OIS/OMS entity would assist FDA in achieving the National Performance Review objectives of streamlining mid-level management, staffers note
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.